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Abstract: Background: Fever control plays a key role in therapy of patients with acute brain injury.
The infusion of cold saline could serve as an alternative or additional method for targeted temperature
management. However, it is difficult to estimate the amount of fluid required to achieve normothermia
merely on the basis of body weight. There is no standardized load management regarding the adminis-
tration of cold saline, and no closed-loop systems based on continuous temperature-controlled feedback
are available. The primary purpose of the present study was to evaluate the feasibility, efficacy, and
safety of a new automated fluid infusion system. Methods: Twelve patients with acute brain injury and
febrile episodes were treated with the automated infusion device tempedy (seiratherm GmbH, Herzoge-
naurach, Germany). Patients were included if bladder temperature still was 37.9 °C after administration
of antipyretic medication, cold washing solutions, and ice packs more than 2 h earlier. The efficacy was
examined by measuring the time and amount of fluid needed to reach and maintain target temperature.
Feasibility and safety were assessed based on recording any technical difficulties with the new device and
the occurrence of clinical signs of fluid overload such as acute pulmonary edema, electrolyte disturbances,
or acid–base dysfunction. Results: The mean time was 73 min (range from 15 to 330 min) and 1650 ml
the mean amount of fluid (21.2 ml/kg; SD 28.5 ml/kg) to reach the target temperature. The mean total
fluid balance to reach and maintain the target temperature in the first 12 h was 1350 ml (SD 1550 ml).
In the first 12 h 89.4% of the time temperature values were in the target range (median 95.3%, range
83.8–10%). No clinical signs of fluid overload such as an acute pulmonary edema or device-related adverse
events occurred. Conclusion: Target temperature management with the new automated infusion device
is feasible. Although we pro- vided first data regarding safety, further controlled randomized studies are
needed to evaluate the long-time safety, as well as the best indications and timing for this cooling device.
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Background: Fever control plays a key role in therapy of patients with acute brain injury. The 
infusion of cold saline could serve as an alternative or additional method for targeted 
temperature management. However, it is difficult to estimate the amount of fluid required to 
achieve normothermia merely on the basis of body weight. There is no standardized load 
management regarding the administration of cold saline, and no closed-loop systems based 
on continuous temperature-controlled feedback are available. The primary purpose of the 
present study was to evaluate the feasibility, efficacy, and safety of a new automated fluid 
infusion system. 
Methods: Twelve patients with acute brain injury and febrile episodes were treated with the 
automated infusion device tempedy (seiratherm GmbH, Herzogenaurach, Germany). Patients 
were included if bladder temperature still was 37.9 °C after administration of antipyretic 
medication, cold washing solutions, and ice packs more than 2 h earlier. The efficacy was 
examined by measuring the time and amount of fluid needed to reach and maintain target 
temperature. Feasibility and safety were assessed based on recording any technical difficulties 
with the new device and the occurrence of clinical signs of fluid overload such as acute 
pulmonary edema, electrolyte disturbances, or acid–base dysfunction. 
Results: The mean time was 73 min (range from 15 to 330 min) and 1650 ml the mean amount 
of fluid (21.2 ml/kg; SD 28.5 ml/kg) to reach the target temperature. The mean total fluid 
balance to reach and maintain the target temperature in the first 12 h was 1350 ml (SD 1550 
ml). In the first 12 h 89.4% of the time temperature values were in the target range (median 
95.3%, range 83.8–10%). No clinical signs of fluid overload such as an acute pulmonary 
edema or device-related adverse events occurred. 
Conclusion: Target temperature management with the new automated infusion device is 
feasible. Although we pro- vided first data regarding safety, further controlled randomized 
studies are needed to evaluate the long-time safety, as well as the best indications and timing 
for this cooling device. 
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Introduction 
Fever is common in patients with acute brain injury, and up to 90% develop a fever at least 
once within 7 days in the intensive care unit [1]. Regardless of its cause, it is linked to higher 
mortality, poor neurological outcome, and increased length of stay in the intensive care unit 
and hospital [1–5]. Greer et al. confirmed this 2008 in a meta-analysis of 14,431 patients with 
a variety of neuro- logical injuries [6]. Therefore, fever control plays a key role in therapy of 
patients with acute brain injury. Several therapeutic options are available to lower the body 
temperature.  Primarily, antipyretic medication, physical cooling methods, and ice pads are 
applied. The next escalation step is the application of various surface or endovascular cooling 
devices. The infusion of cold saline could serve as an alternative or additional method for 
targeted temperature management. Although studies regarding the administration of cold 
saline for fever control appear reasonable [7–10], there are currently no new, reliable results. 
This is also due to the cumbersome application of infusions in order to achieve sufficient 
temperature control. There is no standardized load management regarding the administration 
of cold saline, and there are no closed-loop systems available based on continuous 
temperature-controlled feedback. Moreover, it is difficult to estimate the required amount of 
fluid to achieve normothermia merely on the basis of body weight. Besides, the subsequent 
long-term temperature stabilization via repetitive manual application of infusions would require 
substantial nursing time. 
In this study, we present cases undergoing treatment based on a new automated infusion 
system for temperature control (tempedy®, seiratherm GmbH, Herzogenaurach, Germany). 
Leveraging on the routine i.v. fluid application in intensive care units this stand-alone medical 
device adjusts flow rate and temperature of infusions in order to systemically adjust body core 
temperature, all controlled via feedback loop with standard temperature measuring probes. 
The primary purpose of this study was to evaluate the feasibility and safety of the new device, 
with special focus on the amount of fluid needed to achieve and maintain the target 
temperature. Secondly, the efficacy of the new device was examined, defined as the time and 




The study was approved by the ethics committee of Zurich, Switzerland, and consent was 
obtained from all patients or custodians. Between August 2015 and June 2017, a total of 12 
patients were treated with the automated infusion device (tempedy®, seiratherm GmbH, 
Herzogenaurach, Germany). Three patients suffered from subarachnoid hemorrhage, four 
from intracerebral hemorrhage, one from ischemic stroke, one from status epilepticus with 
PRES, one from septic shock, and two from meningoencephalitis. Inclusion criteria for 10 
patients were intractable fever. Refractory fever was defined according to Badjatia et al., but 
adapted to local treatment standards, i.e., bladder temperature ≥ 37.9 °C, persistent at least 2 
h after administration of antipyretic medication (acetaminophen, novaminsulfon, diclofenac), 
cold washing solutions, and® ice packs [7]. Two patients were treated with tempedy 
immediately after termination of an endovascular cooling period, in order to maintain 
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Fig. 1 tempedy® console and proprietary disposable (left) and top view of the two chambers, pumps, 
and sensor elements (right) 
The tempedy console contains two separate separately tempered chambers in which the 
infusion solution bags are placed. The system can be used with any crystalloid solution 
according to the physician’s discretion (saline, sodium lactate solutions, etc.). Each of the 
chambers is accurately tempered with Peltier elements, and the temperature of the infused 
fluid can range from 4 to 42 °C. The chambers have a maximum liquid storage capacity of 6 
L. The infusion bags are interconnected with an application set which merges the fluid streams 
and leads them in a highly isolated line to the patient access point. This non-additionally 
invasive solution makes use of any existing venous access point with Luer lock such as an 
indwelling peripheral venous cannula or a central access. Two pumps pump the fluid into the 
patient’s body, con- trolled by various sensors for temperature, pressure, and a bubble detector 
to ensure safety. Fluid infusion is performed by two peristaltic pumps, one for each chamber. 
Individual flow rates, as well as the mixing ratio between the cold and warm fluid prior to 
application, are con- trolled by a proprietary algorithm, thereby enabling a controlled fluid 
infusion in the continuous range from 4 to 42 °C. 
The system has a fully automated physiological feedback via temperature probes, suitable for 
different physiological measurement sites, and is controlled by a proprietary algorithm 
adjustable to each patient. The temperature measuring probe of the device in our patients was 
placed in the esophagus. Based on continuous body temperature measurements and 
physicians’ treatment targets for fluid and temperature management, the system automatically 
modulates flow rate and temperature of infusions prior to the application. In case the patient’s 
actual temperature is above a preset temperature threshold, the system will automatically 
infuse cooler fluids (down to 4 °C) in order to achieve the required temperature reduction. 
There is no optimal or standardized duration of therapy for this device, as it strongly depends 
upon the patient specific characteristics and treatment targets set by the caregivers. This novel 
system is approved for clinical use in Europe via the CE mark, and it is also cleared for the 
USA with FDA approval. 
With regard to our patients, the cooling system was set to automatic mode. Target 
temperatures were deter- mined for every patient individually, based on patient characteristics, 
indication, and treatment targets. Patient target temperatures ranged between 36.5 and 38.0 
°C, with a preset tolerance range of 0.5 °C for the first two patients and 0.2–0.3 °C for the 
others. The preset tolerance is an individually predefined patient body temperature range that 
allows for spontaneous temperature fluctuations within this range without triggering the device 
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a target temperature tolerance of 0.3 °C, temperature fluctuations between 37.2 and 37.5 °C 
will not trigger a device intervention. 
The system is cleared for the usage of any intravenous infusion. In this study, however, 
Ringer’s lactate was used in all patients. During the treatment with the device, the 
administration of cold washing solutions and ice packs was discontinued. The antipyretic 
medication was continued. 
All patients were treated at the neurocritical care unit and undergoing daily chest X-rays, 
laboratory analyses and two-hourly blood gas analysis. The treating physicians were specially 
trained with regard to possible side effects of the new device such as pulmonary edema, 
cardiac events, or electrolyte disturbances due to potential fluid overload. Shivering was 
assessed hourly according to the Bedside Shivering Assessment Scale [10]. 
Data from patients treated for at least 12 h without interruption and with a preset tolerance of 




Of the 12 patients treated, four were excluded from the analysis: two due to the fact that 
treatment time was less than 12 h and two patients because the preset temperature tolerance 
of 0.5 °C did not meet the inclusion criteria (inclusion criteria preset tolerance 0.2–0.3 °C). 
Patient characteristics are given in Table 1. 
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Data from eight patients, four men and four women, were analyzed (mean age 48.5 ± 12 years, 
body weight 78.8 ± 19 kg and height 171 ± 8 cm). Seven of the eight patients had an 
endotracheal intubation and were mechanically ventilated. The origin of fever was infectious, 
indicated by the detection of microorganisms in the urine, cerebrospinal fluid, or blood, or signs 
of pulmonary infiltration in chest X-ray (n = 4), or suggested to be so due to a systemic 
inflammatory response with cerebral vasospasm (n = 4). 
The mean duration of application of the cooling device was 53 h (range from 16 h to 142 h). 
The mean time to reach the target temperature was 73 min (range from 15 min to 330 min). 





In the first 12 h, 89.4% of the time temperature values were in the target range (median 95.3%, 
range 83.8– 100%). The mean cooling speed was 1.3 °C/h (± 1.0 °C/h) and the mean amount 
of fluid needed to reduce the temperature by 1 °C was 18.7 ml/kg body weight (± 11.0 ml/kg 
body weight, median 13.1 ml/kg® body weight). For the six patients treated with tempedy for 
24 h or longer the table shows that a relatively higher fluid load was required within the first 12 
h to reach the target temperature. However, with sustained fever therapy and ongoing 
normothermia stabilization, the fluid application was significantly reduced. The installation of 
the cooling device did not cause any technical difficulties. No clinical signs of fluid overload 
such as an acute pulmonary edema occurred. Also, we observed no clinically relevant 
electrolyte disturbances or acid–base dysfunction. To further illustrate the functionality of the 
new device, we illustrate the course of two patients with different indications for target 
temperature management. 
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Figure 2 shows the temperature profile of a patient with intract® able fever and the amount of 
fluids infused by tempedy, starting with an esophageal temperature of 38.2 °C. A target 
temperature of 37.5 °C with a tolerance of + 0.2 °C was determined. After infusion of two 
boluses of cold saline (overall 538 ml, 8.3 ml/kg body weight), the patient reached the target 
temperature. During the following 4 h, the patient repeatedly developed fever. Due to the preset 
limits for fluid infusion and the closed-loop system, the device applied further boluses of cold 
fluid. After 4.5 h the patient reached a stable condition with normothermia and no further need 
of cold fluids. In fact, for the next 7 h the esophageal temperature continually decreased which 
suggests a confirmation of an effect previously reported by Rajek et al. [8]. This subsequent 
decline is most likely due to the reduction of both the total body heat content and the core 
metabolic rate. For this case, the total amount of fluids infused by the device in the first 12 h 
was 3195 ml. In parallel to the device, the patient received a further 1200 ml of fluid infusions 
within the first 12 h. Taking the diuresis of the patient into account, after 12 h the total fluid 




Fig. 2 Temperature profile and amount of fluids infused in a single patient with intractable fever of 38.2 °C 
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Figure 3 depicts the temperature profile of a patient who was initially treated for several days 
with an endovascular cooling device to induce hypothermia. 
Due to the increased risk of an additional thromboembolic event during long-term application 
of intravascular catheters, the patient was switched over to the tempedy® device for the 
subsequent temperature stabilization, starting with a temperature of 36.2 °C. The target 
temperature too was 36.2 °C with a tolerance of 0.2 °C. 
With an initial bolus of 200 ml cold saline, the patient reached the target temperature but 
repeatedly developed temperatures above the defined target during the following 10 h. The 
device reacted with repeated infusions of boluses of cold saline. To maintain the target 
temperature, the patient received 3601 ml of cold fluids within 12 h and an additional amount 
of 990 ml was infused in parallel to the device. Taking the diuresis into account, the total fluid 
balance over the first 12 h was 991 ml. 
 
 
Fig. 3 Temperature profile of a patient treated to maintain normothermia after previous endovascular cooling 
 
Discussion 
The analysis of this small patient series was performed to determine the safety, feasibility, and 
efficacy of a new automated infusion cooling device for target temperature management. In 
our findings the median time to target temperature was 15 min and the median amount of fluid 
to target temperature was 540 ml, 8 ml/kg body weight, respectively. The median amount of 
fluid applied to maintain the target temperature during the first 12h was 2040 ml, 25 ml/kg body 
weight, respectively. Taking the diuresis into account, the median total fluid balance in the first 
12 h was 961 ml. 
Furthermore, our data indicate that due to the fever reduction to normothermic levels, the fluid 
load was initially higher, whereas the subsequent normothermia maintenance required less. 
This leads to a slightly positive fluid balance for the first 12 h. However, over   the whole course 
of treatment we observed the following effects: firstly, the device required less fluids for the 
subsequent normothermia stabilization, and secondly, some patients had a transiently 
increased diuresis; consequently, the initially observed slightly positive fluid balance was 
reduced toward a neutral fluid balance. Besides the fluids that were applied by the device, 
further fluids were infused in parallel (the application of drugs, nutrition, etc.). Within the first 
12 h, 66% of the overall fluid load was cooling fluids applied via the device. Hence, the overall 
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fluid application could potentially be further reduced by applying a higher percentage of fluids 
via the device. seiratherm GmbH is currently working on developing an extension that also 
allows the infusion of col- loids, blood-based products, and nutrition solutions. 
No serious adverse events such as pulmonary edema were observed. This has also been 
observed in other study groups using larger fluid amounts for hypothermia induction [11]. 
Neither did we observe shivering, most likely as a result of 11 of 12 patients being under deep 
analgosedation due to the severity of their disease. One patient received standard medication 
only for analgesia (morphine, acetaminophen, novaminsulfon). In patients with acute brain 
injury, pyrexia has been identified as an independent risk factor for increased  mortality and 
poorer neurological outcome [5, 6, 12, 13]. Even though the relationship is proven, and fever 
control is highly recommended, there is a lack of recommendation on how to reach and 
maintain normothermia. Several therapeutic options are available for fever treatment. 
Primarily, antipyretic medication and physical cooling methods are applied. Antipyretics, such 
as, acetaminophen, metamizole, and non-steroidal anti-inflammatory drugs act on the 
hypothalamic set point. In brain-injured patients, the integrity of the thermoregulatory system 
is rarely given. Therefore, antipyretic agents alone are usually ineffective for fever treatment 
[5]. In the PAIS trial, 6 g/day acetaminophen in stroke patients resulted in a mean body 
temperature reduction of only 0.26 °C compared to placebo, and the study could not report an 
improved outcome for treatment with acetaminophen [14]. Some pharmacologic interventions 
are even potentially harmful, e.g., parenteral diclofenac infusion might decrease brain tissue 
oxygen tension in aneurysmal subarachnoid hemorrhage [15]. 
The next escalation step after antipyretic medication for fever treatment is the application of 
various surface or endovascular cooling devices. Both systems have been shown to be 
effective in inducing and maintaining normothermia for prolonged periods [16]. Cooling with 
water or air circulating blankets is usually preferred for fever control, while endovascular 
methods, due to the risk of thromboembolic complications, are more commonly restricted to 
therapeutic hypothermia [17]. Both systems use a continuous feedback algorithm based on 
continuous patient temperature assessment. Water at a specific temperature, based on the 
prescribed, programmed mode of therapy and the patient’s current temperature, is circulating 
through cooling pads attached to the skin or through endovascular catheters. Newer data show 
that endovascular cooling has advantages over surface cooling when it comes to induction 
speed, stability and temperature control, overshoot avoidance, working load for medical 
personal and rewarming control [18]. Although both systems are proven to be most effective, 
their disadvantages have to be taken into account. Both systems are quite costly and require 
a certain work load and time for installation. Frequently, anti-shivering therapy is needed. With 
surface cooling, there is the risk of skin lesions. Furthermore, endovascular cooling contains 
the risk of mechanical complications due to the catheter insert and the risk of central venous 
line infections [19]. In addition, there is a documented increased thromboembolic risk due to 
the intravascular catheter [17]. Therefore, especially for fever reduction, noninvasive and more 
cost-effective methods should be the first choice. In 2006, Badjatia et al. showed that the 
application of boluses with cold salines represents a safe, feasible, and inexpensive method 
to achieve normothermia in patients with refractory fever [7]. Patients still suffering from 
refractory fever > 38 °C more than 2 h after the administration of acetaminophen (650 mg 
orally) and placement of a water-circulating cooling blanket were treated with a bolus of cold 
saline (mean 29.2 ml/Kg). With the infusion of cold saline, all patients reached nor- mothermia. 
Moreover, it was also possible to maintain normothermia for the next 24 h. Although the study 
postulated that the maintenance of normothermia was likely to be attributed to the continued 
use of surface cooling with water-circulating blankets, the achievement of normothermia was 
most likely due to the effect of the cold saline bolus. Even earlier, Rajek et al. already quantified 
the cooling effects of cold infusions and investigated the higher than expected reduction in 
core temperatures [8]. This study measured core and peripheral tissue temperatures as well 
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as energy expenditure in healthy volunteers before and after infusion of 4 °C fluid, and was 
able to conclude and quantify that the reduced core temperature resulted from three factors: 
(1) 50–55% from the systemic cooling effects of the actual fluids, (2) ca. 30% from the fact that 
the reduction in core heat content remained partially constrained to core tissues, and (3) 10–
20% from the fact that the cutaneous heat loss exceeded metabolic heat production. 
This also explains the advantage of cold saline over surface cooling. The infusion of cold saline 
reduces core temperatures not only by reduction of the core metabolic rate and total body heat 
content but also by isolating the core and peripheral thermal compartments. The major 
potential disadvantage of the new method is a risk of fluid overload, potentially leading to 
cardiac and respiratory failure with imminent pulmonary edema [20]. Whereas in sepsis 
additional fluids might be beneficial [11], special caution should be used in elderly patients with 
frequently occurring latent heart failure or in all patients with cardiac or renal disease and 
reduced urinary output. Thus, it seems reasonable to try to achieve the target temperature with 
the least possible amount of fluid. Therefore, the temperature of the fluid that actually enters 
the patient should be as close to the recommended 4 °C as possible [9]. To date, the cold 
saline for infusion is kept in a refrigerator before being administered to the patient. At the 
bedside there usually is an interruption of the cooling chain; thus, the temperature of the cold 
saline administered to the patient® is more likely to be 10–15 °C than 4 °C. In our tempedy 
test series the temperature sensor in the tubing set showed an average infusion temperature 
of 4–5 °C. Compared to the manual application of refrigerated saline for fever therapy [5], this 
system offers three advantages. First, the device increases effectiveness as the infusion 
temperature remains stable throughout the application. Second, the amount of infused fluid is 
deter- mined for every patient individually and applied patient adaptive in order to reduce 
burden. Third, the device enables active pumping and precise flow rates which appears to be 
of advantage compared to simple drip infusion or application by pressure cuffs. In summary, 
this could explain why we needed smaller amounts of fluid to reach normothermia in the initial 
phase of fever reduction in comparison to the fluid requirements the Badjatia study. 
The study has several strong limitations: The number   of patients was small, and there was a 
substantial heterogeneity regarding the treatment periods. Side effects of long-term treatment 
cannot be excluded. Furthermore, antipyretic medication was continued. Synergistic effects 
with the physical cooling are highly probable, as antipyretics prevent hypothalamic counter 
regulation. Another limitation is the fact that the software was continually improved throughout 
the course of patient enrollment. The first patients were treated with a first software release, 
whereas the next software updates implemented some improvements regarding the feedback 
algorithm. Consequently, it could be postulated that the first treatments lacked the benefit of 




In our small pilot study we showed the feasibility and efficacy of the tempedy cooling device. 
Although we pro- vided first data regarding safety, there is the potential risk of fluid overload. 
However, the new closed-loop temperature feedback, the stability of the temperature of the 
infused fluid, and the individualized settings reduce the risk of fluid overload compared to 
manual administration. Further controlled randomized studies are needed to evaluate the long-
time safety, as well as the best indications and timing for this cooling device. 
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